FrancophonIA/ELRC3.0 huggingface dataset:
English: The other ingredients are: hypromellose, magnesium stearate, methacrylic acid-ethyl acrylate copolymer, microcrystalline cellulose, sodium hydroxide, titanium dioxide and carnauba wax.
Slovenian: Pomožne snovi so: hipromeloza, magnezijev stearat, kopolimer metakrilne kisline in etilakrilata, mikrokristalna celuloza, natrijev hidroksid, titanov dioksid in karnauba vosek.
English: Rare: hyponatremia
Slovenian: Redki: hiponatriemija.
English: In a phase 3, double-blind, placebo-controlled, event-driven trial (RIVER-PCI) in 2604 patients aged ≥18 years with a history of chronic angina and incomplete revascularisation after percutaneous coronary intervention (PCI) patients were up-titrated to 1000 mg twice daily (dosage not approved in the current SmPC).
Slovenian: V dvojno slepi, s placebom kontrolirani dogodkovno vodeni študiji (RIVER-PCI) faze 3, ki je vključevala 2.604 bolnikov starih ≥ 18 let z anamnezo kronične angine pektoris in nepopolne revaskularizacije po perkutani koronarni intervenciji (PKI) so bili bolniki titrirani do 1000 mg ranolazina dvakrat na dan (odmerek, ki v SmPC ni odobren).
English: Your doctor may decide to give you a lower dose or take other precautions if any of these apply to you.
Slovenian: Če kar koli od navedenega velja za vas, vam bo morda zdravnik dal manjši odmerek ali uporabil druge previdnostne ukrepe.
English: Concomitant administration of Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.
Slovenian: Sočasna uporaba antiaritmikov razreda Ia (npr. kinidina) ali razreda III (npr. dofetilida, sotalola), razen amiodarona.
English: Ελλάδα MENARINI HELLAS AE Τηλ: +30 210 8316111-13
Slovenian: MENARINI HELLAS AE Τηλ: +30 210 8316111-13
English: Blister pack: 5 years Bottle pack: 4 years
Slovenian: Pakiranje v plastenki: 4 leta
English: Ranexa resulted in significant decreases in the number of angina attacks per week (p = 0.028) and consumption of short-acting nitroglycerin (p = 0.014) compared to placebo.
Slovenian: Zdravilo Ranexa je v primerjavi s placebom pomembno zmanjšalo število napadov angine na teden (p = 0,028) in porabo hitro delujočega nitroglicerina (p = 0,014).
English: In an oral high-dose tolerability study in angina patients, the incidence of dizziness, nausea, and vomiting increased in a dose-dependent manner.
Slovenian: V študiji tolerabilnosti velikih peroralnih odmerkov pri bolnikih z angino pektoris se je pogostnost omotice, navzee in bruhanja večala sorazmerno z odmerkom.
English: CYP3A4 or P-gp inhibitors: Ranolazine is a substrate of cytochrome CYP3A4.
Slovenian: Zaviralci encima CYP3A4 ali P-gp: Ranolazin je substrat citokroma CYP3A4.
English: Chronic toxicity studies in rats indicated that treatment was associated with adrenal changes at exposures slightly greater than those seen in clinical patients.
Slovenian: Študije kronične toksičnosti pri podganah so pokazale, da je pri izpostavljenosti, ki je nekoliko večja od tiste pri kliničnih bolnikih, zdravljenje povezano s spremembami nadledvične žleze.
English: Musculoskeletal and connective tissue disorders Uncommon: pain in extremity, muscle cramp, joint swelling, muscular weakness.
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva Občasni: bolečina v okončinah, mišični krči, otekanje sklepov, mišična slabost.
English: Common: dizziness, headache.
Slovenian: Pogosti: omotica, glavobol.
English: Менарини България” ЕООД тел.
Slovenian: Менарини България”
English: Drug-drug interactions: Co-administration with CYP3A4 inducers is expected to lead to lack of efficacy.
Slovenian: Interakcije med zdravili: Pričakovati je, da bo sočasna uporaba spodbujevalcev encima CYP3A4 zmanjšala učinkovitost.
English: Always take this medicine exactly as your doctor has told you to.
Slovenian: Pri jemanju tega zdravila vedno upoštevajte zdravnikova navodila.
English: Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent increases in average ranolazine steady-state concentrations of 1.5- to 2.4-fold.
Slovenian: Diltiazem (od 180 do 360 mg dnevno), zmerno močan zaviralec encima CYP3A4, povzroča od 1,5- do 2,4-kratno od odmerka odvisno povečanje povprečne koncentracije ranolazina v stanju dinamičnega ravnovesja.
English: The maximum dose of Ranexa is 750 mg twice a day.
Slovenian: Največji odmerek zdravila Ranexa je 750 mg dvakrat na dan.
English: Concomitant administration of potent CYP3A4 inhibitors is contraindicated (see sections 4.3 and 4.5).
Slovenian: Sočasna uporaba močnih zaviralcev CYP3A4 je kontraindicirana (glejte poglavji 4.3 in 4.5).
English: There was a 2.5- to 3-fold increase in steady-state AUC as the dose was increased from 500 mg to 1000 mg twice daily.
Slovenian: V dinamičnem ravnovesju je bilo povečanje AUC 2,5-3-kratno, ko se je odmerek povečal s 500 mg na 1000 mg dvakrat na dan.
English: Tacrolimus, ciclosporin, sirolimus, everolimus: Increased plasma concentrations of tacrolimus, a CYP3A4 substrate, have been observed in patients after ranolazine administration.
Slovenian: Takrolimus, ciklosporin, sirolimus, everolimus: Po uporabi ranolazina je bila pri bolnikih povečana koncentracija takrolimusa, substrata CYP3A4, v plazmi.
English: Carton containing blister strips or carton containing HDPE bottle and bottle label.
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI Škatla s pretisnimi omoti ali škatla s stekleničko iz HDPE in oznaka na steklenički.
English: Sodium: This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release tablet, that is to say essentially ‘sodium-free'.
Slovenian: Natrij: To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na 1 tableto s podaljšanim sproščanjem, kar v bistvu pomeni 'brez natrija'.
English: Ranexa may cause dizziness, blurred vision, diplopia, confusional state, coordination abnormal, and hallucination (see section 4.8), which may affect the ability to drive and use machines.
Slovenian: Zdravilo Ranexa lahko povzroči omotico, zamegljen vid, diplopija, stanje zmedenosti, motnje v koordinaciji in halucinacije (glejte poglavje 4.8), kar lahko vpliva na sposobnost vožnje in upravljanja s stroji.
English: The risk for increased exposure leading to adverse events in these different subgroups is higher in patients lacking CYP2D6 activity (poor metabolisers, PM) than subjects with CYP2D6 metabolising capacity (extensive metabolisers, EM) (see section 5.2).
Slovenian: Tveganje za povečano izpostavitev, ki povzroča neželene učinke, je v teh podskupinah večje pri bolnikih, pri katerih encim CYP2D6 ni aktiven (bolniki s počasno presnovo , BPP), kot pri osebah s presnovno aktivnostjo encima CYP2D6 (bolniki z močno presnovo, BMP) (glejte poglavje 5.2).
English: Ranolazine AUC was unaffected in patients with mild hepatic impairment but increased 1.8-fold in patients with moderate impairment.
Slovenian: Vrednost AUC ranolazina pri bolnikih z blago jetrno okvaro ni bila spremenjena, vendar se je pri bolnikih z zmerno okvaro povečala za 1,8-krat.
English: Ranexa is a medicine used in combination with other medicines to treat angina pectoris, which is a chest pain or discomfort that you feel anywhere along the upper part of your body between your neck and upper abdomen, often brought on by exercise or too much activity.
Slovenian: Angina pektoris je bolečina v prsnem košu ali neprijeten občutek kjer koli v zgornjem delu telesa med vratom in zgornjim delom trebuha, ki se pogosto pojavita pri telesni vadbi ali pretirani aktivnosti.
English: • Patients with low weight (≤ 60 kg) (see sections 4.2, 4.8, and 5.2).
Slovenian: • Bolniki z majhno telesno maso ( 60 kg) (glejte poglavja 4.2, 4.8 in 5.2).
English: In patients with mild or moderate renal impairment (creatinine clearance ≥ 30-80 ml/min) compared to those with normal renal function (creatinine clearance > 80 ml/min), the most commonly reported events and their placebo-corrected frequencies included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
Slovenian: Pri bolnikih z blago do zmerno ledvično okvaro (kreatininski očistek  30-80 ml/min), v primerjavi z bolniki z normalnim delovanjem ledvic (kreatininski očistek > 80 ml/min), so dogodki, o katerih so poročali najpogosteje, in njihova pogostnost z odšteto pogostnostjo pri placebu vključevali: obstipacijo (8% v primerjavi s 4%), omotico (7% v primerjavi s 5%) in navzeo (4% v primerjavi z 2%).
English: In general, the type and frequency of adverse events reported in patients with low body weight (≤ 60 kg) were similar to those of patients with higher weight (> 60 kg); however, the placebocorrected frequencies of the following common adverse events were higher in low body weight than heavier patients: nausea (14% versus 2%), vomiting (6% versus 1%), and hypotension (4% versus
Slovenian: Na splošno sta bili vrsta in pogostnost neželenih dogodkov, o katerih so poročali pri bolnikih z majhno telesno maso ( 60 kg), podobni kot pri bolnikih z večjo telesno maso (> 60 kg); vendar so pogostnosti naslednjih neželenih učinkov z odšteto pogostnostjo pri placebu bile večje pri bolnikih z majhno telesno maso kot pri bolnikih z večjo telesno maso: navzea (14% v primerjavi z 2%), bruhanje (6% v primerjavi z 1%) in hipotenzija (4% v primerjavi z 2%).
English: Dose adjustment of sensitive CYP3A4 substrates (e.g. simvastatin, lovastatin) and CYP3A4 substrates with a narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus) may be required as RANEXA may increase plasma concentrations of these drugs.
Slovenian: Prilagoditev odmerka občutljivih substratov za CYP3A4 (npr. simvastatina, lovastatina) in substratov CYP3A4 z ozkim terapevtskim oknom (npr. ciklosporin, takrolimus, sirolimus, everolimus) bo morda potrebna, saj lahko zdravilo RANEXA poveča plazemsko koncentracijo teh zdravil.
English: The AUC of metabolites increased with decreased renal function.
Slovenian: Vrednost AUC presnovkov se je povečala z zmanjšanjem delovanja ledvic.
English: Elderly: Dose titration in elderly patients should be exercised with caution (see section 4.4).
Slovenian: Starejši bolniki: Odmerek za starejše bolnike je treba titrirati previdno (glejte poglavje 4.4).
English: Renal impairment: In a study evaluating the influence of renal function on ranolazine pharmacokinetics, ranolazine AUC was on average 1.7- to 2-fold higher in subjects with mild, moderate, and severe renal impairment compared with subjects with normal renal function.
Slovenian: Ledvična okvara: V študiji, v kateri so ocenjevali vpliv delovanja ledvic na farmakokinetiko ranolazina, je bila pri bolnikih z blago, zmerno ali hudo ledvično okvaro vrednost AUC ranolazina povprečno od 1,7- do 2-krat večja kot pri bolnikih z normalnim delovanjem ledvic.
English: Moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Slovenian: Zmerna ali huda jetrna okvara (glejte poglavji 4.2 in 5.2).
English: The active substance in Ranexa is ranolazine.
Slovenian: Zdravilna učinkovina v zdravilu Ranexa je ranolazin.
English: In a pharmacokinetic study in healthy volunteers, steady-state Cmax was, on average, approximately 1770 (SD 1040) ng/ml, and steady-state AUC0-12 was, on average, 13,700 (SD 8290) ng x h/ml following a dose of 500 mg twice daily.
Slovenian: V študiji farmakokinetike pri zdravih prostovoljcih je bila pri odmerku 500 mg dvakrat na dan Cmax v stanju dinamičnega ravnovesja povprečno približno 1770 (standardni odklon 1040) ng/ml, AUC0-12 v stanju dinamičnega ravnovesja pa je bila povprečno 13.700 (SO 8290) ng x h/ml.
English: Ear and labyrinth disorders Uncommon: vertigo, tinnitus.
Slovenian: Ušesne bolezni, vključno z motnjami labirinta Občasni: vertigo, tinitus.
English: • Patients with moderate to severe CHF (NYHA Class III-IV) (see sections 4.2 and 5.2).
Slovenian: • Bolniki z zmernim do hudim CHF (III.-IV. razreda po razvrstitvi NYHA) (glejte poglavji 4.2
English: Ask your doctor for advice about driving or using machines.
Slovenian: Glede vožnje in upravljanja strojev se posvetujte z zdravnikom.
English: At 500 mg twice daily, subjects lacking CYP2D6 activity (poor metabolisers, PM) had 62% higher AUC than subjects with CYP2D6 metabolising capacity (extensive metabolisers, EM).
Slovenian: Pri odmerku 500 mg dvakrat na dan je bila pri osebah, pri katerih ni aktivnosti encima CYP2D6 (slabi presnavljavci, SP), vrednost AUC za 62% večja kot pri osebah s presnovno aktivnostjo encima CYP2D6 (dobri presnavljavci, DP).
English: 375 mg tablet: macrogol, polysorbate 80, Blue #2/Indigo Carmine Aluminium Lake (E132) 500 mg tablet: macrogol, talc, polyvinyl alcohol-part hydrolyzed, iron oxide yellow (E172), iron oxide red (E172)
Slovenian: 375-miligramska tableta: makrogol, polisorbat 80, modro aluminijevo barvilo indigotin št. 2 (E132) 500-miligramska tableta: makrogol,smukec, polivinilalkohol - delno hidroliziran, železov oksid,
English: Uncommon: lethargy, syncope, hypoaesthesia, somnolence, tremor, postural dizziness, paresthesia.
Slovenian: Občasni: letargija, sinkopa, hipestezija, somnolenca, tremor, posturalna omotica, parestezija.
English: depression (nefazodone), or heart rhythm disorders (e.g. quinidine, dofetilide, or sotalol).
Slovenian: (zaviralce proteaze), depresije (nefazodon) ali motenj srčnega ritma (npr. kinidin, dofetilid ali sotalol).
English: Ranexa demonstrated greater efficacy than placebo in prolonging exercise time at trough at 12 weeks for both doses studied when used as an add-on therapy.
Slovenian: Zdravilo Ranexa je bilo v primerjavi s placebom pri obeh raziskovanih odmerkih po 12. tednu učinkovitejše pri podaljšanju časa telesne vadbe pri najmanjši koncentraciji v plazmi, kadar so ga uporabljali kot dodatno zdravljenje.
English: Congestive heart failure (CHF): Dose titration in patients with moderate to severe CHF (NYHA Class III-IV) should be exercised with caution (see sections 4.4 and 5.2).
Slovenian: Kongestivno srčno popuščanje (Congestive Heart Failure - CHF): Pri titriranju odmerka za bolnike z zmernim do hudim CHF (III.-IV. razreda po razvrstitvi NYHA) je potrebna previdnost (glejte poglavji 4.4 in 5.2).
English: There was a significantly lower incidence of arrhythmias in patients treated with Ranexa (80%) versus placebo (87%), including ventricular tachycardia ≥ 8 beats (5% versus 8%).
Slovenian: Pri bolnikih, ki so prejemali zdravilo Ranexa (80%), je bila pogostnost aritmije pomembno manjša kot pri bolnikih, ki so prejemali placebo (87%), vključno z ventrikularno tahikardijo  8 utripov (5% v primerjavi z 8%).
English: Of the most commonly reported, the following events occurred more often with Ranexa (placebo-corrected frequencies) in elderly (≥ 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Slovenian: Med neželenimi dogodki, o katerih so poročali najpogosteje, so ob jemanju zdravila Ranexa naslednji bili pogostejši (pogostnost pri placebu je odšteta) pri starejših ( 75 let) kot pri mlajših (< 75 let) bolnikih: obstipacija (8% v primerjavi s 5%), navzea (6% v primerjavi s 3%), hipotenzija (5% v primerjavi z 1%) in bruhanje (4% v primerjavi z 1%).
English: Hepatic impairment: The pharmacokinetics of ranolazine have been evaluated in patients with mild or moderate hepatic impairment.
Slovenian: Jetrna okvara: Farmakokinetiko ranolazina so ocenjevali pri bolnikih z blago do zmerno jetrno okvaro.
English: Examples of such drugs include certain antihistamines (e.g. terfenadine, astemizole, mizolastine), certain antiarrhythmics (e.g. quinidine, disopyramide, procainamide), erythromycin, and tricyclic antidepressants (e.g. imipramine, doxepin, amitriptyline).
Slovenian: Primeri takšnih zdravil so nekateri antihistaminiki (npr. terfenadin, astemizol in mizolastin), nekateri antiaritmiki (npr. kinidin, disopiramid in prokainamid), eritromicin in triciklični antidepresivi (npr. imipramin, doksepin in amitriptilin).
English: Drugs transported by the Organic Cation Transporter-2 (OCT2): Plasma exposure of metformin (1000 mg twice daily) increased 1.4- and 1.8-fold in subjects with type 2 diabetes mellitus when coadministered with RANEXA 500 mg and 1000 mg twice daily respectively.
Slovenian: Zdravila, ki se prenašajo z organskim kationskim prenašalcem 2 s prenašalcem (OCT-2- Organic Cation Transporter-2): Izpostavljenost metformina (1000 mg dvakrat na dan) v plazmi se je povečala za 1,4- oziroma za 1,8- krat pri bolnikih s sladkorno boleznijo tipa 2, ki so sočasno jemali zdravilo Ranexa 500 mg oziroma 1000 mg dvakrat na dan.
English: Uncommon: anxiety, insomnia, confusional state, hallucination.
Slovenian: Občasni: anksioznost, insomnija, stanje zmedenosti, halucinacije.
English: A population-based analysis of combined data from patients and healthy volunteers demonstrated that the slope of the plasma concentration-QTc relationship was estimated to be 2.4 msec per 1000 ng/ml, which is approximately equal to a 2- to 7-msec increase over the plasma concentration range for ranolazine 500 to 1000 mg twice daily.
Slovenian: Analiza kombiniranih populacijskih podatkov pri bolnikih in zdravih osebah je pokazala, da je ocena naklona razmerja med koncentracijo v plazmi in intervalom QTc 2,4 msec na 1000 ng/ml, kar približno ustreza od 2- do 7-milisekundnemu povečanju znotraj območja koncentracije ranolazina pri odmerku od 500 do 1000 mg dvakrat na dan.
English: In a large outcome study (MERLIN-TIMI 36) in 6,560 patients with UA/NSTEMI ACS, there was no difference in the risk of all-cause mortality (relative risk ranolazine:placebo 0.99), sudden cardiac death (relative risk ranolazine:placebo 0.87), or the frequency of symptomatic documented arrhythmias (3.0% versus 3.1%) between Ranexa and placebo when added to standard medical therapy (including beta-blockers, calcium channel blockers, nitrates, anti-platelet agents, lipid-lowering medicinal products, and ACE inhibitors).
Slovenian: V veliki študiji izida (MERLIN-TIMI 36) pri 6560 bolnikih z UA/NSTEMI AKS ni bilo razlike pri tveganju za umrljivost zaradi vseh vzrokov (razmerje relativnega tveganja med ranolazinom in placebom 0,99), nenadni srčni smrti (razmerje relativnega tveganja med ranolazinom in placebom 0,87) ali pogostnosti simptomatičnih dokumentiranih aritmij (3,0% v primerjavi s 3,1%) med zdravilom Ranexa in placebom, kadar so ga dodali standardnemu zdravljenju (vključno z betablokatorji, zaviralci kalcijevih kanalčkov, nitrati, protitrombocitnimi zdravili, zdravili za zmanjšanje koncentracije lipidov in zaviralci ACE).
English: Therefore the exposure to metoprolol or other CYP2D6 substrates (e.g. propafenone and flecainide or, to a lesser extent, tricyclic antidepressants and antipsychotics) may be increased during co-administration with Ranexa, and lower doses of these medicinal products may be required.
Slovenian: Zaradi tega se med uporabo zdravila Ranexa lahko poveča izpostavljenost metoprololu ali drugim substratom encima CYP2D6 (npr. propafenonu in flekanidu ali, v manjši meri, tricikličnim antidepresivom in antipsihotikom) in bodo morda potrebni manjši odmerki teh zdravil.
English: Rare: angioedema, allergic dermatitis, urticaria, cold sweat, rash.
Slovenian: Redki: angioedem, alergijski dermatitis, urtikarija, mrzel pot, izpuščaj.
English: • Mild to moderate renal impairment (creatinine clearance 30-80 ml/min) (see sections 4.2, 4.8,
Slovenian: • Blaga do zmerna ledvična okvara (kreatininski očistek 30-80 ml/min) (glejte poglavja 4.2, 4.8
English: It is recommended that tacrolimus blood levels are monitored when co-administering Ranexa and tacrolimus and that tacrolimus dosage is adjusted accordingly.
Slovenian: Priporočljivo je, da se vrednost takrolimusa v krvi, ko se ga jemlje skupaj z zdravilom Ranexa, redno spremlja in da je zatorej odmerek prilagojen.
English: Dose titration in patients with low weight should be exercised with caution (see sections 4.4, 4.8, and 5.2).
Slovenian: Pri titriranju odmerka za bolnike z majhno telesno maso je potrebna previdnost (glejte poglavja 4.4, 4.8 in 5.2).
English: Rare: amnesia, depressed level of consciousness, loss of consciousness, coordination abnormal, gait disturbance, parosmia.
Slovenian: Redki: amnezija, stanje zmanjšane zavesti, izguba zavesti, parozmija, motnje v koordinaciji, motnje v drži.
English: Uncommon: abdominal pain, dry mouth, dyspepsia, flatulence, stomach discomfort.
Slovenian: Občasni: bolečina v trebuhu, suha usta, dispepsija, flatulenca, neprijeten občutek v želodcu.
English: Additional excipients for 375 mg tablet: Macrogol
Slovenian: Dodatne pomožne snovi v 375-miligramski tableti: makrogolpolisorbat 80
English: However, the elderly may have increased ranolazine exposure due to age-related decrease in renal function.
Slovenian: Vendar je lahko izpostavljenost ranolazinu pri starejših bolnikih večja zaradi poslabšanja delovanja ledvic, povezanega s starostjo.
English: Ranexa 750 mg prolonged-release tablets contain lactose monohydrate.
Slovenian: Zdravilo Ranexa 750-miligramske tablete s podaljšanim sproščanjem vsebujejo laktozo monohidrat.
English: Ranexa resulted in significant decreases in the number of angina attacks per week and consumption of short-acting nitroglycerin compared to placebo.
Slovenian: Zdravilo Ranexa je v primerjavi s placebom pomembno zmanjšalo število napadov angine na teden in porabo hitro delujočega nitroglicerina.
English: There was no renal toxicity related to these findings.
Slovenian: V povezavi s tem pa toksičnega učinka na ledvice ni bilo.
English: • Concomitant administration of P-gp inhibitors (see sections 4.2 and 4.5).
Slovenian: • Sočasna uporaba zaviralcev P-gp (glejte poglavji 4.2 in 4.5).
English: A population analysis of combined data from 1,308 patients and healthy volunteers demonstrated a mean increase in QTc from baseline of 2.4 msec per 1000 ng/ml ranolazine plasma concentration.
Slovenian: Analiza kombiniranih podatkov 1308 bolnikov in zdravih prostovoljcev je pokazala povprečno povečanje intervala QTc za 2,4 ms od izhodiščne vrednosti pri koncentraciji ranolazina v plazmi 1000 ng/ml.
English: • Elderly (see sections 4.2, 4.8, and 5.2).
Slovenian: • Starejši bolniki (glejte poglavja 4.2, 4.8 in 5.2).
English: • Concomitant administration of moderate CYP3A4 inhibitors (see sections 4.2 and 4.5).
Slovenian: • Sočasna uporaba zmernih zaviralcev CYP3A4 (glejte poglavji 4.2 in 4.5).
English: Digoxin: An increase in plasma digoxin concentrations by an average of 1.5-fold has been reported when Ranexa and digoxin are co-administered.
Slovenian: Digoksin: Pri sočasni uporabi zdravila Ranexa in digoksina so poročali o povprečnem 1,5-kratnem zvišanju koncentracije digoksina v plazmi.
English: This value is consistent with data from pivotal clinical studies, where mean changes from baseline in QTcF (Fridericia's correction) after doses of 500 and 750 mg twice daily were 1.9 and 4.9 msec, respectively.
Slovenian: Ta vrednost sovpada s podatki osrednjih kliničnih študij, pri katerih je bila srednja vrednost sprememb od izhodiščne vrednosti intervala QTcF (Fridericijev popravek) po odmerku 500 mg dvakrat na dan 1,9 ms, po odmerku 750 mg dvakrat na dan pa 4,9 ms. Naklon je večji pri bolnikih s klinično pomembno jetrno okvaro.
English: Uncommon: fatigue, peripheral oedema.
Slovenian: Občasni: utrujenost, periferni edem.
English: Ranexa is contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.3 and 5.2).
Slovenian: Uporaba zdravila Ranexa je kontraindicirana pri bolnikih s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) (glejte poglavji 4.3 in 5.2).
English: (itraconazole, ketoconazole, voriconazole, posaconazole), HIV infection (protease inhibitors),
Slovenian: glivičnih okužb (itrakonazol, ketokonazol, vorikonazol ali posakonazol), okužbe z virusom HIV